Onconase Shows Promising Results in Treating Non-Small Cell Lung Cancer
Researchers led by Intae Lee, PhD, Department of Radiology, University of Pennsylvania, have presented new data on the effectiveness of Onconase (ranpirnase) against non-small cell lung cancer (NSCLC) at the 47th Annual Meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO). The study, titled "The Enhanced Efficacy of Cisplatin and Carboplatin by the RNase Onconase on A549 Human Lung Cancer Xenografts of Nude Mice," demonstrated the potential of Onconase in treating NSCLC, a type of cancer that affects millions worldwide.
Key Takeaways:
- Onconase demonstrated efficacy in inhibiting tumor growth of A549 human NSCLC cells and inducing apoptosis (programmed cell death) of those cells.
- Onconase enhanced the cytotoxic effects of cisplatin and carboplatin when administered simultaneously or after Onconase treatment.
- Onconase effectively inhibited tumor growth in large-size tumors previously treated unsuccessfully with various drugs.
- Cisplatin and carboplatin showed limited tumoricidal effects in comparison to Onconase.
- The studies highlighted the potential of Onconase as a novel therapeutic agent for NSCLC.
Statistics:
- 47th Annual Meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO)
- Onconase inhibited tumor growth of A549 human NSCLC cells by [ specify percentage]
- Onconase-induced apoptosis rate in A549 human NSCLC cells: [ specify percentage]
- Cisplatin and carboplatin efficacy rates in treating NSCLC: [ specify percentage]
- Number of patients with NSCLC treated unsuccessfully with various drugs: [ specify number]
Sources:
- Health & Medicine Week published by NewsRx.com via Health & Medicine Week Editors